Who owns LYELL IMMUNOPHARMA INC COM NEW?
- Ticker: LYEL
- CUSIP Number: 55083r203
Tip: Access positions for across all investors
Analyze quarterly positions in Lyell Immunopharma with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Lyell Immunopharma stock
Who bought or sold LYELL IMMUNOPHARMA INC COM NEW this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Arch Venture Corp | 2.8M | $85M | 0% | Dec 2025 |
|
| MWG Management | 1.0M | $16M | 100% | Sep 2025 |
|
| Vanguard Group | 826k | $25M | 6% | Dec 2025 |
|
| Foresite Capital Management IV | 800k | $25M | 0% | Dec 2025 |
|
| Orland Properties | 755k | $23M | 0% | Dec 2025 |
|
| Almitas Capital | 578k | $18M | 0% | Dec 2025 |
|
| Foresite Capital Management V | 477k | $15M | 0% | Dec 2025 |
|
| Citadel Advisors | 356k | $5.8M | 24% | Sep 2025 |
|
| venBio Partners | 338k | $10M | -29% | Dec 2025 |
|
| Alphabet | 293k | $9.0M | 0% | Dec 2025 |
|
| BlackRock | 182k | $5.6M | 3% | Dec 2025 |
|
| Geode Capital Management | 163k | $5.0M | 25% | Dec 2025 |
|
| Susquehanna International | 159k | $4.9M | 887% | Dec 2025 |
|
| Sc China Holding | 152k | $3.9M | 0% | Dec 2025 |
|
| Millennium Management | 125k | $2.0M | 140% | Sep 2025 |
|
| Invesco | 99k | $3.0M | 100% | Dec 2025 |
|
| Goldman Sachs Group | 97k | $3.0M | 100% | Dec 2025 |
|
| Rbf Capital | 96k | $1.6M | -4% | Sep 2025 |
|
| MIC Capital Management UK | 87k | $2.7M | 0% | Dec 2025 |
|
| Charles Schwab Investment Management | 85k | $2.6M | 7% | Dec 2025 |
|
| Marshall Wace | 73k | $2.3M | 100% | Dec 2025 |
|
| State Street Corporation | 52k | $1.6M | 53% | Dec 2025 |
|
| Johnson & Johnson | 41k | $1.3M | 0% | Dec 2025 |
|
| Ikarian Capital | 41k | $1.3M | -6% | Dec 2025 |
|
| Renaissance Technologies | 40k | $1.2M | -38% | Dec 2025 |
|
| Northern Trust | 30k | $932k | 8% | Dec 2025 |
|
| Canada Pension Plan Investment Board | 29k | $478k | 0% | Sep 2025 |
|
| Two Sigma Investments | 21k | $338k | 107% | Sep 2025 |
|
| Susquehanna Portfolio Strategies | 21k | $640k | 0% | Dec 2025 |
|
| Clarius | 20k | $614k | 0% | Dec 2025 |
|
| Bridgeway Capital Management | 18k | $292k | 0% | Sep 2025 |
|
| Barclays | 16k | $492k | 1240% | Dec 2025 |
|
| UBS Group | 13k | $406k | -38% | Dec 2025 |
|
| Jane Street | 12k | $382k | 100% | Dec 2025 |
|
| Point72 Asset Management | 12k | $353k | 100% | Dec 2025 |
|
| Boothbay Fund Management | 9.5k | $293k | -22% | Dec 2025 |
|
| Qube Research & Technologies | 9.1k | $279k | 100% | Dec 2025 |
|
| ExodusPoint Capital Management | 8.5k | $262k | 100% | Dec 2025 |
|
| Raymond James Financial | 7.9k | $243k | 100% | Dec 2025 |
|
| Candriam Luxembourg S.C.A. | 7.6k | $235k | 100% | Dec 2025 |
|
| BBR Partners | 6.8k | $210k | 100% | Dec 2025 |
|
| Royal Bank of Canada | 4.2k | $69k | 16648% | Sep 2025 |
|
| Diadema Partners | 3.8k | $117k | 100% | Dec 2025 |
|
| China Universal Asset Management | 3.5k | $106k | 3% | Dec 2025 |
|
| Bnp Paribas Arbitrage, Snc | 3.2k | $98k | 793% | Dec 2025 |
|
| FMR | 2.7k | $44k | -12% | Sep 2025 |
|
| Acadian Asset Management | 1.7k | $51k | -85% | Dec 2025 |
|
| Tower Research Capital | 1.2k | $37k | -36% | Dec 2025 |
|
| Mirae Asset Global Investments | 1.0k | $32k | 39% | Dec 2025 |
|
| Jones Financial Companies, L.L | 1.0k | $32k | -49% | Dec 2025 |
|
| Advisors Asset Management | 567.00 | $18k | 0% | Dec 2025 |
|
| Jpmorgan Chase & Co | 490.00 | $8.0k | 100% | Sep 2025 |
|
| Gf Fund Management | 416.00 | $13k | 1% | Dec 2025 |
|
| Wells Fargo & Company | 125.00 | $3.8k | 100% | Dec 2025 |
|
| Advisor Group Holdings | 124.00 | $3.8k | 100% | Dec 2025 |
|
| MAI Wealth Advisors | 100.00 | $3.1k | 0% | Dec 2025 |
|
| Us Bancorp | 58.00 | $1.8k | 0% | Dec 2025 |
|
| Daiwa Securities Group | 45.00 | $999.999000 | 0% | Dec 2025 |
|
| Simplex Trading | 37.00 | $1.1k | -77% | Dec 2025 |
|
| GAMMA Investing | 35.00 | $1.1k | 0% | Dec 2025 |
|
| NISA Investment Advisors | 25.00 | $770.000000 | 0% | Dec 2025 |
|
| CWM | 20.00 | $1.0k | -52% | Dec 2025 |
|
Who sold out of Lyell Immunopharma?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| OrbiMed Advisors | Sep 2025 | 52k | $840k |
| Trexquant Investment | Sep 2025 | 10k | $167k |
| Rangeley Capital | Sep 2025 | 10k | $162k |
| Shell Asset Management Company | Jun 2025 | 320.00 | $3.0k |